Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?

Biochemical Pharmacology

Volumn 62, Issue 11, 2001, Pages 1433-1438

  Fiorucci, Stefano ^a   Meli, Rosaria ^b   Bucci, Mariarosaria ^b   Cirino, Giuseppe ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

5 LOX inhibitors; COX; COX inhibitors; Leukotrienes; NSAIDs; Prostaglandins

Indexed keywords

5 [[1,5 BIS(4 METHOXYPHENYL)PYRAZOL 3 YL]DIMETHOXYMETHYL] 2 CHLOROBENZAMIDE; ANTIRHEUMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME INHIBITOR; ER 34122; INDOMETACIN; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LICOFELONE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; S 2474; TEPOXALIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BRONCHOSPASM; DIGESTIVE SYSTEM ULCER; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; HUMAN; HYPOTHESIS; INFLAMMATION; INFLAMMATORY DISEASE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE;

EID: 0035584272     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00747-X     Document Type: Note

References (61)

1. Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity
4. Tissue-selective inhibition of prostaglandin (PG) synthesis: Anti-inflammatory without gastropathy?
5. Distribution of COX-1 and COX-2 in normal and inflammed tissues
6. Cyclooxygenases 1 and 2
7. 2 synthase (cyclooxygenase) in human monocytes
8. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
9. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
10. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
11. Leukotrienes and prostaglandins in asthma
12. Indomethacin-induced leukocyte adhesion in mesenteric venules: Role of lipoxygenase products
13. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis
14. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide
15. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis
16. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
17. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
18. Cyclooxygenase in rat spinal cord: Selective induction of COX-2 during peripheral inflammation
19. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized controlled trial
20. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
21. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
22. Nociception in cyclooxygenase isoenzyme-deficient mice
23. COX-2 inhibitors
24. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
25. Cyclooxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy
26. Cyclooxygenase-2 induction has a profound inhibitory effect on human airway smooth muscle cell proliferation
27. Enhanced expression of cyclooxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma
28. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma
29. Aspirin sensitive rhinosinusitis and asthma
30. Fish oil fatty acid and cardiovascular function: Epidemiology and biochemical mechanisms
31. Activation of the pulmonary arachidonic acid system and its consequences for hemodynamics and fluid balance
32. Slow-reacting substances of anaphylaxis: Identification of leukotrienes C-1 and D from human and rat sources
33. Leukotrienes as a target in asthma therapy
34. Current asthma therapies and issues in asthma management
35. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes
36. 4 receptor expressed on eosinophils
37. 4 receptor
38. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects
39. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases
40. 4-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis
41. 4 pathway to inflammation control
42. 4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis
43. 2. A new therapeutic target in inflammation and immunological disorders
44. Interaction between prostaglandins and leukotrienes
45. Allergen-stimulated release of mediators into sheep bronchoalveolar lavage fluid. Effect of cyclooxygenase inhibition
46. 2 analog in animals and in man
47. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma
48. The effects of ML3000 on antigen-induced responses in sheep
49. Modulation of AA metabolites in the treatment of rheumatoid arthritis
50. Effect of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice
51. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model
52. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (γ-sultam) skeleton: Cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase
53. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: Antiinflammatory without gastropathy?
54. Cytokine-modulating activity of tepoxalin, a new potential antirheumatic
55. Tepoxalin: A dual cycloxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile
56. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase
57. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]- acetic acid
58. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury
59. Gastrointestinal tolerance of 2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]- acetic acid in rat
60. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]- acetic acid in experimental animals